Leap zeroes in on subgroup for DKN-01, Keytruda combo

Shares of Leap tumbled Tuesday as investors digested updated data from the Phase I trial of DKN-01 that showed a lower response than reported in March for the mAb in combination with Keytruda for advanced gastroesophageal junction and

Read the full 382 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE